NDA for Macrilen™ for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date
Aeterna Zentaris Inc. (AEZS)
Last aeterna zentaris inc. earnings: 11/7 06:28 pm
Check Earnings Report
US:NASDAQ Investor Relations:
zentaris.com
Company Research
Source: Business Wire
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the “Company”) today announced that it has been notified by the U.S. Food and Drug Administration (“FDA”), that the Company’s New Drug Application (“NDA”) seeking approval of Macrilen™ (macimorelin) for the evaluation of growth hormone deficiency in adults (“AGHD”) has been accepted as a complete response to the FDA’s November 5, 2014 Complete Response Letter and granted a PDUFA date of December 30, 2017. David A. Dodd, President and Chief Executive Officer of the Company stated, “We are pleased that the FDA has formally accepted our resubmitted NDA and that it is under active review with an end-of-year PDUFA date. We remain confident that the FDA will approve our NDA and, therefore, we are moving forward with our preparations to launch the product in the first quarter of 2018.” The Company also announces that Mr
Show less
Read more
Impact Snapshot
Event Time:
AEZS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AEZS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AEZS alerts
High impacting Aeterna Zentaris Inc. news events
Weekly update
A roundup of the hottest topics
AEZS
News
- Aeterna Zentaris Announces Effective Date of Share ConsolidationGlobeNewswire
- Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
AEZS
Sec Filings
- 5/1/24 - Form 6-K
- 4/30/24 - Form F-1/A
- 3/28/24 - Form 6-K
- AEZS's page on the SEC website